USP Responding To Congress’ Questions On Medicare Formulary Guidelines
Executive Summary
The U.S. Pharmacopeia has been providing congressional committees with information as it moves toward finalizing its model formulary guidelines for the Medicare prescription drug benefit
You may also be interested in...
USP hires former PBM exec as general counsel
Susan de Mars joins U.S. Pharmacopeia as senior VP and general counsel from the law firm Reed Smith Nov. 15. She was formerly senior VP-governmental affairs for benefit manager AdvancePCS, where she focused on Medicare drug benefit issues and the development of compliance guidance for the pharmaceutical industry. USP is in the midst of developing model formulary guidelines for the Medicare prescription drug program (1"The Pink Sheet" Oct. 25, 2004, p. 26). De Mars succeeds Joseph Valentino, who is retiring from USP Dec. 15...
USP hires former PBM exec as general counsel
Susan de Mars joins U.S. Pharmacopeia as senior VP and general counsel from the law firm Reed Smith Nov. 15. She was formerly senior VP-governmental affairs for benefit manager AdvancePCS, where she focused on Medicare drug benefit issues and the development of compliance guidance for the pharmaceutical industry. USP is in the midst of developing model formulary guidelines for the Medicare prescription drug program (1"The Pink Sheet" Oct. 25, 2004, p. 26). De Mars succeeds Joseph Valentino, who is retiring from USP Dec. 15...
Broad Medicare Formularies Would Negatively Impact Rx Industry – PCMA
Strict formulary requirements imposed on plan sponsors under the Medicare prescription drug benefit would be self-defeating for pharmaceutical manufacturers, Pharmaceutical Care Management Association CEO Mark Merritt argued Oct. 25